[
  {
    "ts": null,
    "headline": "Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis",
    "summary": "AMGN gains momentum as Uplizna wins FDA approval for generalized myasthenia gravis, adding a twice-yearly dosing option in a crowded autoimmune market.",
    "url": "https://finnhub.io/api/news?id=248460a2eebe7df6576d25fbb647abb238f6008f7add18806728bea02d00bc18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765545720,
      "headline": "Here's How AMGN Benefits From FDA Nod to Uplizna in Myasthenia Gravis",
      "id": 137769300,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "AMGN gains momentum as Uplizna wins FDA approval for generalized myasthenia gravis, adding a twice-yearly dosing option in a crowded autoimmune market.",
      "url": "https://finnhub.io/api/news?id=248460a2eebe7df6576d25fbb647abb238f6008f7add18806728bea02d00bc18"
    }
  }
]